Phaseline

Targets › PDE3B

PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B): drug programs, companies and trials

1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.

Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signaling. (UniProt, Q13370)

Open in Phaseline: the race on PDE3B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tenax TherapeuticsLevosimendan (TNX-103)
Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator
PDE3A, PDE3B, TNNC1, TNNI3, TNNT2Phase 3Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic ShockJun 2028

Conditions

Pulmonary Hypertension Associated With HFpEF (1) Pulmonary Hypertension (1) Mechanical Ventilation (1) Cardiogenic Shock (1)

Modalities

small molecule (1)

Companies

Tenax Therapeutics (1)

Related targets

PDE3A (1) TNNC1 (1) TNNI3 (1) TNNT2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.